AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Valdecoxib (Bextra[TM]), a selective inhibitor of cyclo-oxygenase 2 (COX-2), is indicated for the treatment of acute and chronic signs and symptoms of adult rheumatoid arthritis and osteoarthritis as well as for the relief of pain associated with primary dysmenorrhea (1). Severe cutaneous adverse reactions (ARs) associated with valdecoxib, including erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported internationally (2, 3). The Canadian product monograph (1) contains the following information:
* a recommendation to discontinue valdecoxib therapy at the first appearance of a rash or other sign of hypersensitivity;